Skip to main content

Table 4 Association between biomarker serum levels and outcome

From: Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program

Serum biomarker

PFS

OS

Median (days)

HR (95 % CI)

Median (days)

HR (95 % CI)

P value

P value

VEGF-A

low-level baseline

166

0.533

329

0.602

high-level baseline

91

(0.318–0.895)

270

(0.356–1.018)

P  = 0.017

P = 0.058

sVEGFR2

low-level baseline

107

1.682

293

1.148

high-level baseline

167

(1.014–2.789)

330

(0.648–1.927)

P  = 0.044

P = 0.601

VEGF-D

low-level baseline

123

1.670

310

0.888

high-level baseline

159

(0.760 –3.673)

300

(0.527–1.496)

P = 0.200

P = 0.654

SDF-1α

low-level baseline

160

0.749

300

0.783

high-level baseline

129

(0.417–1.321)

329

(0.429–1.431)

P = 0.310

P = 0.427

  1. HR hazard ratio, PFS progression free survival, OS overall survival, CI confidence interval. P < 0.05 marked in boldface